Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review.
Pathology case of the month. A recurrent vesicle on the plantar aspect of the foot. Primary cutaneous CD30- positive T-cell lymphoproliferative disorder, consistent with lymphomatoid papulosis.
A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group.
Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L, Zain J, Rosen ST, Querfeld C.
Cancer Treat Res. 2019;176:249-268. doi: 10.1007/978-3-319-99716-2_12.
Cutaneous CD30-Positive Lymphoproliferative Disorders.
Kempf W.
Surg Pathol Clin. 2014 Jun;7(2):203-28. doi: 10.1016/j.path.2014.02.001.
DUSP22-rearranged primary cutaneous CD30-positive T-cell lymphoproliferative disorders and adult T-cell leukemia/lymphoma frequently share the LEF1+/TIA1- immunophenotype.
Chen BJ, Hsieh SM, Hsieh TH, Jhuang JY, Kao YC.
Hum Pathol. 2024 Aug;150:58-66. doi: 10.1016/j.humpath.2024.07.002. Epub 2024 Jul 4.
Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W, Kerl K, Mitteldorf C.
Semin Cutan Med Surg. 2018 Mar;37(1):24-29. doi: 10.12788/j.sder.2018.001.
Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.
Montes-Moreno S.
Pathologie (Heidelb). 2023 Dec;44(Suppl 3):136-139. doi: 10.1007/s00292-023-01258-6. Epub 2023 Nov 27.
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin.
Stein T, Robak T, Biernat W, Robak E.
J Clin Med. 2024 Jan 31;13(3):823. doi: 10.3390/jcm13030823.
A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W.
Semin Diagn Pathol. 2017 Jan;34(1):22-35. doi: 10.1053/j.semdp.2016.11.005. Epub 2016 Nov 29.
Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K, Gu J, Aung PP, Nagarajan P, Curry JL, Huen A, Ivan D, Prieto VG, Tetzlaff MT, Duvic M, Miranda RN, Vega F, Torres-Cabala CA.
Virchows Arch. 2021 Aug;479(2):377-383. doi: 10.1007/s00428-021-03056-y. Epub 2021 Feb 18.
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris MÁ.
Haematologica. 2019 Feb;104(2):226-235. doi: 10.3324/haematol.2018.197152. Epub 2019 Jan 10.
